2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2524

Application of The 2012 Systemic Lupus International Collaborating Clinics Classification Criteria On a Regional Swedish Systemic Lupus Erythematosus Register
Abstract Number: 2184

Application Of The Bonexpert Method For Bone Age and Bone Health Assessment In Patients With Juvenile Idiopathic Arthritis
Abstract Number: 846

Applying Choosing Wisely: Identifying Inefficiencies Of Antinuclear Antibody Subserology Testing In a Safety Net Health System
Abstract Number: 1916

Approaches and Challenges To Reducing Wait Times For Total Hip and Knee Replacement
Abstract Number: 761

Apremilast For The Treatment Of Behçet’s Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study
Abstract Number: L4

Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
Abstract Number: 331

Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Abstract Number: 317

Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Abstract Number: 816

Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Abstract Number: 2106

Aquatic Exercise Training For Fibromyalgia: A Systematic Review
Abstract Number: 1212

Are Different Disease Subtypes With Distinct Clinical Expression Present In Familial Mediterranean Fever: Results Of a Cluster Analysis
Abstract Number: 1697

Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?
Abstract Number: 184

Are Physician Gender, Age and Clinical Experience Associated With Discrepancy In Global Disease Score In Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis? Data From The Nationwide Danbio Registry
Abstract Number: 2296

Are SDAI50 and DAS28 Response Measures Comparable In Early Rheumatoid Arthritis Patients?
Abstract Number: 1343

Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].